| Year |
Citation |
Score |
| 2019 |
Houl JH, Ye Z, Brosey CA, Balapiti-Modarage LPF, Namjoshi S, Bacolla A, Laverty D, Walker BL, Pourfarjam Y, Warden LS, Babu Chinnam N, Moiani D, Stegeman RA, Chen MK, Hung MC, et al. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nature Communications. 10: 5654. PMID 31827085 DOI: 10.1038/S41467-019-13508-4 |
0.6 |
|
| 2018 |
Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, et al. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Advances. 2: 2400-2411. PMID 30254104 DOI: 10.1182/Bloodadvances.2018018564 |
0.329 |
|
| 2017 |
Pawlyn C, Loehr A, Tytarenko R, Deshpande S, Sun J, Fedorchak K, Mughal TI, Davies F, Walker B, Raponi M, Morgan GJ. Loss of heterozygosity in multiple myeloma: A role for PARP inhibition? Journal of Clinical Oncology. 35: 8026-8026. DOI: 10.1200/Jco.2017.35.15_Suppl.8026 |
0.316 |
|
| 2015 |
Pawlyn C, Kaiser MF, Stein CK, Wardell CP, Macleod V, Edmondson R, Barlogie B, Walker B, Morgan GJ, Davies FE. Abstract 3516: EZH2 overexpression in myeloma patients shortens survival and in-vitro data supports a potential new targeted treatment strategy Cancer Research. 75: 3516-3516. DOI: 10.1158/1538-7445.Am2015-3516 |
0.357 |
|
| 2008 |
Burden RE, Snoddy P, Buick RJ, Johnston JA, Walker B, Scott CJ. Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Molecular Cancer Therapeutics. 7: 538-47. PMID 18347141 DOI: 10.1158/1535-7163.Mct-07-0528 |
0.308 |
|
| 2005 |
Crawford LJA, Ovaa H, Walker B, Chauhan D, Anderson KC, Morris TCM, Irvine AE. Evaluation of the Specificity and Cytotoxicity of Three Proteasome Inhibitors. Blood. 106: 3366-3366. DOI: 10.1182/Blood.V106.11.3366.3366 |
0.303 |
|
| Show low-probability matches. |